Patients with severe depression, active suicidal thoughts, eating disorders, or complex psychiatric conditions require careful assessment before treatment
The International Diabetes Federation reports there were about 589 million adults around the world living with diabetes in 2024, with 90% of these having type 2 diabetes
The drug does not cause weight loss directly instead, it makes you want to eat less
In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]
Molecular Weight: 1,419.53 DA